Northwire Canada EditionSunday, October 18, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Production / Operations

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+(TM) at SITC 2025

By The Northwire Desk — AI Analysis Nov 07, 2025 · 07:30 BCT · 13.98 BRIACELL THERAPEUTICS CORP. J
BCT · Price

Executive Summary

  • BriaCell announced pre‑clinical evidence of strong innate and adaptive immune activation and durable anti‑cancer activity for its next‑generation Bria‑OTS+ platform, presented as a poster at the SITC 40th Anniversary Annual Meeting.
  • The data highlight rapid tumor cell cytotoxicity for lead candidates Bria‑BRES+ (breast cancer) and Bria‑PROS+ (prostate cancer), supporting broad applicability across multiple solid‑tumor indications.
  • Both candidates have completed GMP manufacturing and are slated for Phase 1/2a clinical evaluation, with Bria‑PROS+ backed by a $2 million NCI SBIR award.

Key Details

  • Presentation: “Redefining Cancer Vaccines: Bria‑OTS+ Integrates Trained Innate Immunity and Adaptive Memory to Overcome Immune Resistance,” Abstract No. 353, SITC 2025 Annual Meeting, National Harbor, MD (Nov 7‑9, 2025).
  • Preclinical Findings – Fast Acting: Bria‑BRES+ and Bria‑PROS+ rapidly activated key innate and adaptive immune components in animal models, leading to coordinated tumor cell killing.
  • Preclinical Findings – Durable Response: Both candidates generated sustained anti‑cancer immune responses, suggesting potential for prolonged clinical benefit.
  • Broad Applicability: Positive results support expansion of the Bria‑OTS+ platform into additional solid‑tumor indications beyond breast and prostate cancer.
  • Manufacturing Status: GMP‑manufactured batches of Bria‑BRES+ and Bria‑PROS+ are complete and ready for upcoming clinical trials.
  • Clinical Plans: Phase 1/2a studies for both candidates are planned; Bria‑PROS+ will be supported by a $2 million NCI SBIR award announced Aug 25, 2025.
  • Poster Access: A copy of the poster will be available at https://briacell.com/scientific‑publications/.

Notable Quotes

“We are thrilled with the comprehensive, powerful, and long‑lasting immune activation demonstrated by Bria‑OTS+ in our preclinical studies… we believe will translate into meaningful anti‑cancer immune responses in the clinic.” – Miguel A. Lopez‑Lago, PhD, Chief Scientific Officer

“These findings add to the growing body of evidence supporting our Bria‑OTS+ platform’s unique mechanism of action for novel personalized cancer immunotherapies… we look forward to confirming these encouraging preclinical results in planned clinical trials.” – Dr. William V. Williams, President & CEO

Read the original news release →

More from BRIACELL THERAPEUTICS CORP. J

Jun 25, 2026 · 07:30

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)

M&A / Property Jun 02, 2026 · 16:05

BriaCell Closes $4.7M Discounted Offering as Pre-Revenue Burn Rate Demands Cash, Dilution Weighs on Sentiment

Financings Jun 01, 2026 · 07:30

BriaCell’s ASCO Data Validates Pipeline Trajectory, But Dilutive Capital Raise and Phase 3 Event-Driven Timeline Keep Near-Term Upside Capped

Other May 31, 2026 · 19:59

BriaCell Therapeutics Announces Pricing of Offering

Financings May 31, 2026 · 03:20

Briacell prices shares of $4.7M offering at $3.25 each

Financings May 26, 2026 · 07:30

Safety Confirmed but Efficacy Uncertainty Weighs on Valuation Amidst Dilution Concerns

Other